Nagy G, Brózik M, Varga L, Füst G, Kirschfink M, Kiss E, Gergely P
Central Laboratory of Immunology, Semmelweis University of Medicine, Budapest, Hungary.
Lupus. 2000;9(1):19-25. doi: 10.1177/096120330000900105.
Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). Plasma levels of C3b(Bb)P and SC5b-9 were moderately, those of C1rs-C1inhibitor (C1rs-C1inh) were markedly elevated in patients with clinically inactive SLE, compared with healthy controls. The difference between active and inactive stages of the disease was best reflected by C3b(Bb)P plasma concentration (P<0.001), which also showed the highest correlation with the SLEDAI (Rs=0.41 P<0.001) and which was the most useful in distinguishing active and inactive sample pairs as well. The difference between SC5b-9 levels in the active and inactive stages was also significant (P=0.007), while that of C1rs-C1inh did not differ significantly (P=0.136). The correlation of the SLEDAI with SC5b-9 was 0.3 (P=0.015), while with C1rs-C1inh it was 0.21 (P=0. 089). These findings suggest that the measurement of complement activation products, especially that of the alternative pathway, are sensitive markers of the activity of SLE and can be used for clinical purposes.
在健康供体以及临床活动期和非活动期系统性红斑狼疮（SLE）患者中，检测了补体激活产物，如特异性针对经典途径激活的C1rs - C1inh、特异性针对替代途径激活的C3b(Bb)P以及特异性针对补体级联反应共同末端途径的SC5b - 9。与健康对照相比，临床非活动期SLE患者血浆中C3b(Bb)P和SC5b - 9水平中度升高，C1rs - C1抑制剂（C1rs - C1inh）水平显著升高。疾病活动期和非活动期之间的差异最好通过C3b(Bb)P血浆浓度来反映（P<0.001），其与SLE疾病活动指数（SLEDAI）的相关性也最高（Rs = 0.41，P<0.001），并且在区分活动和非活动样本对方面也最有用。活动期和非活动期SC5b - 9水平的差异也具有显著性（P = 0.007），而C1rs - C1inh的差异不显著（P = 0.136）。SLEDAI与SC5b - 9的相关性为0.3（P = 0.015），与C1rs - C1inh的相关性为0.21（P = 0.089）。这些发现表明，补体激活产物的检测，尤其是替代途径的检测，是SLE活动的敏感标志物，可用于临床目的。
